GCILungLife AI to present LungLB cancer test data at AMP annual meeting
As in any walk of life, if a business has developed a major step forward in technology, then it is critical to raise awareness of the improved performance across the target market.
In the medical world, one of the best ways of doing this is showcasing the breakthrough product/service at an industry conference, where key opinion leaders can ask questions and be further educated about the significant clinical and cost benefits.
Similarly, () , a developer of next-generation early-stage lung cancer tests, said this morning that it would be formally presenting 2 abstract submissions (or scientific documents) regarding its flagship LungLB blood test at the Association for Molecular Pathology's (AMP) 2024 Annual Meeting & Expo in Vancouver, Canada from 19th-23rd November, alongside also being included within the November 2024 issue of The Journal of Molecular Diagnostics.
CEO Paul Pagano commenting: "We are excited to have these two abstracts accepted for both presentation and publication by the AMP and believe this marks another important step in the pathway to commercialisation.
"AMP brings together a diverse community of physicians, scientists, and laboratory professionals from academic and community medical centres, government, and industry. We are looking forward to furthering discussions that allow us to demonstrate our commitment to advancing early detection of lung cancer and making a significant impact in this critical area of healthcare."
In terms of the numbers, house broker Investec has a 171p/share target price and is forecasting revenues to climb from $0.1m in FY24 to $0.5m and $1.2m over the next two years.
Follow News & Updates from LungLife AI:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.